Pfizer announces that if necessary it will be able to provide a vaccine adapted to the Omicron variant of Covid in the spring.
Sabine Bruckner, head of Pfizer in Switzerland, says this in an interview with the newspaper 'Blick'.
"We still don't know if this vaccine will be needed," notes Bruckner.
Pfizer is therefore working on two fronts at the same time, explains the manager.
On the one hand it is studying to what extent the current serum is effective against the new variants, on the other hand it is developing modifications in case it becomes necessary to adapt it.
